Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-25. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
=== In the brain === VIP is also found in the brain and some autonomic nerves: One region includes a specific area of the suprachiasmatic nuclei (SCN), the location of the 'master circadian pacemaker'. See SCN and circadian rhythm below. VIP in the pituitary helps to regulate prolactin secretion; it stimulates prolactin release in the domestic turkey. Additionally, the growth-hormone-releasing hormone (GH-RH) is a member of the VIP family and stimulates growth hormone secretion in the anterior pituitary gland. VIP is also expressed in a subtype of inhibitory interneuron in various regions of the brain.
=== Pharmacokinetics === Suvomipic is used topically on the scalp instead of orally for potential safety and tolerability reasons. As an example, MPCs and pyruvate availability also prominently regulate stem cells and cellular growth in the intestines. The drug is said to be unstable in blood, which limits the risk of systemic absorption and side effects. It is said to have been engineered to be 1,000 times more effective at "penetrating" skin than blood. No suvomipic was detected in circulation with topical administration to the scalp in clinical studies.
=== Other work === In October 2015, she became the celebrity ambassador for Gillette Venus and Oral-B. On 21 March 2023, Willis partnered with Absolute Collagen for their 'Strong in your own skin' campaign.
== Nitrogen-16 == The radioisotope 16N is the dominant radioactivity source in the coolant water of nuclear reactors cooled by water during normal operation. It is produced from 16O (in water) via an (n,p) reaction, in which the 16O atom captures a neutron and expels a proton. It has a short half-life of 7.13 seconds, but its decay back to 16O produces high-energy gamma radiation (6.13 MeV principal line). Because of this, access to the primary coolant piping in a pressurised water reactor must be restricted during reactor power operation. It is a sensitive and immediate indicator of leaks from the primary coolant system to the secondary steam cycle and is the primary means of detection for such leaks.
== Collaboration == Tecemotide was developed – until Clinical trial phase II – by the Canadian biotech company Biomira Inc., which changed its company name to Oncothyreon Inc. in 2007. Oncothyreon is now located in Seattle, Washington, and it changed its name to SGEN after a merger and acquisition in March 2018. In 2001, Merck KGaA, of Darmstadt, Germany, entered into a collaboration and supply agreement with Biomira. In 2007, Merck KGaA acquired the exclusive worldwide marketing rights from Biomira, and Merck KGaA has since then been entirely responsible for the further clinical development of tecemotide. In 2008, Merck KGaA acquired the manufacturing rights for tecemotide from Oncothyreon. In 2011, Ono Pharmaceutical Company, of Japan, acquired a co-development and co-marketing license for tecemotide in Japan; Ono paid Merck KGaA 5 million euros.
Sources: en.wikipedia.org
Soy sauce (sometimes called soya sauce in British English) is a liquid condiment of Chinese origin, traditionally made from a fermented paste of soybeans, roasted grain, brine, and Aspergillus oryzae or Aspergillus sojae molds (kōji). It is recognized for its saltiness and pronounced umami taste. Soy sauce was created in its current form about 2,200 years ago during the Western Han dynasty of ancient China. Since then, it has become an important ingredient in East and Southeast Asian cooking as well as a condiment worldwide.
== Other uses == Opus (mythology), a son of Zeus Opus, Greece, a city in ancient Locris, Greece Opus (Elis), a town in ancient Elis, Greece Opus (architecture), generic term for "construction method", "construction material", "masonry", in use in Ancient Rome OPUS (chromatography), a line of chromatography columns manufactured by Repligen Corporation OPUS (psychiatry), a Danish early intervention program for people with schizophrenia spectrum disorders Opus Film, a Polish film production company
==== Yellow armbands ==== Following Adam Ramanauskas's personal battle with cancer, a "Clash for Cancer" match against Melbourne was launched in 2006. This was a joint venture between Essendon and the Cancer Council of Victoria to raise funds for the organisation. Despite a formal request to the AFL being denied, players wore yellow armbands for the match, which resulted in the club being fined $20,000. In 2007, the AFL agreed to allow yellow armbands to be incorporated into the left sleeve of the jumper. The 'Clash for Cancer' match against Melbourne has become an annual event, repeated in subsequent seasons, though in 2012, 2013, 2014 and 2016, Hawthorn (twice), the Sydney Swans and Brisbane Lions were the opponents in those respective seasons instead of Melbourne. In 2009, the jumpers were auctioned along with yellow boots worn by some players during the match.
Bisphosphonate Bisphosphonates are either administered orally or intravenously. They reduce bone resorption. Mechanism of action: Bisphosphonate binds to the mineral component of the bone and inhibits enzymes (i.e. farnesyl-pyrophosphate synthase) responsible for bone formation, osteoclast recruitment and osteoclast function. This type of drug has a high affinity for hydroxyapatite and stays in bone tissue for a long period of time, with alendronate, it has a half-life of approximately ten years. The risk of a patient having MRONJ after discontinuing this medication is unknown. There are suggestions that bisphosphonate may inhibit the proliferation of soft tissue cells and increases apoptosis. This may result in delayed soft tissue healing. Examples of bisphosphonates: : Zoledronic acid (Reclast, Zometa), Risedronate (Actonel), Alendronate (Fosamax), Etidronate (Didronel), Ibandronate (Boniva), Pamidronate (Aredia), Tiludronate (Skelid). Denosumab Denosumab is a monoclonal antibody which is administrated subcutaneously. It inhibits osteoclast differentiation and activation, reduces bone resorption, improves bone density and lessens skeletal-related events associated with metastasis. Mechanism of action: The drug binds to receptor activator nuclear factor κB ligand (RANKL), preventing the interaction with RANK. It does not bind to bone and its effect on bone diminishes in 9 months. Osteoanabolic drugs
==== "Depression Baby" ==== During the 1930s, the North American Car Company produced a one-of-a-kind, four-wheeled ice-bunker reefer intended to serve the needs of specialized shippers who did not generate enough product to fill a full-sized refrigerator car. NADX #10000 was a 22-foot (6.71 m)-long, all-steel car that resembled the forty-and-eights used in Europe during World War I. The prototype weighed 13.5 short tons (12.2 t; 12.1 long tons) and was outfitted with a 1,500 lb (680 kg) ice bunker at each end. The car was leased to Hormel and saw service between Chicago, Illinois and the southern United States. The concept failed to gain acceptance with eastern railroads, and no additional units were built.
Sources: en.wikipedia.org
Atha sold coffee in the California area, but proposed to James Folger II that he open and manage a Folgers Coffee plant in Texas. The company grew exponentially after Atha opened the Texas plant. Under the mid-20th century leadership of Peter Folger, the brand became one of the principal coffee concerns in North America. In 1960, the construction of a Folger Coffee Company plant in New Orleans was started due to new shipping routes from Central America. Procter & Gamble acquired Folger's in 1963 and removed the apostrophe from its name. On August 9, 1969, company heiress Abigail Folger was stabbed to death in Los Angeles as part of the Manson Family's Tate–LaBianca murders. P&G announced in January 2008 that Folgers would be spun off into a separate Cincinnati-based company but reversed itself that June and announced Folgers would be acquired by the end of 2008 by The J.M. Smucker Company. Utilizing a rare financial technique called a Reverse Morris Trust, Smucker purchased Folgers in November 2008 and made it a subsidiary.
=== Removal === It is possible for a person to live without a pancreas, provided that the person takes insulin for proper regulation of blood glucose concentration and pancreatic enzyme supplements to aid digestion.
=== Chemical synthesis === The chemical synthesis is similar to the biosynthesis, starting from the unsaturated compound without a cyclopropane ring, the vaccenic acid. In a Simmons-Smith reaction, a carbene is added to the double bond of the unsaturated fatty acid; diiodomethane and zinc are used to form the carbene. The Simmons-Smith reaction is stereospecific, for the preparation of cis-11,12-methylenoctadecenoic acid (lactobacillic acid) the cis-11-octadecenoic acid (cis-vaccenoic acid) is used. This can be of natural origin or synthesized from 11-octadecic acid.
== Food chain versus food web == A food chain differs from a food web as a food chain follows a direct linear pathway of consumption and energy transfer. Natural interconnections between food chains make a food web, which are non-linear and depict interconnecting pathways of consumption and energy transfer.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.